MedPath

Chloride ion

Generic Name
Chloride ion
Drug Type
Small Molecule
Chemical Formula
Cl
CAS Number
16887-00-6
Unique Ingredient Identifier
Q32ZN48698

Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Autism Spectrum Disorder

Phase 1
Recruiting
Conditions
Safety Issues;Effect of Drugs
Interventions
Biological: Autologous Umbilical Cord Blood
First Posted Date
2021-02-24
Last Posted Date
2021-02-24
Lead Sponsor
Guangdong Women and Children Hospital
Target Recruit Count
25
Registration Number
NCT04768816
Locations
🇨🇳

Guangdong Women and Children's Hospital and Health Institute, Guangzhou, Guangdong, China

Comparison of Two Analgesic Strategies After Scheduled Caesarean

Phase 4
Completed
Conditions
Analgesia
Interventions
First Posted Date
2021-02-16
Last Posted Date
2024-08-05
Lead Sponsor
GCS Ramsay Santé pour l'Enseignement et la Recherche
Target Recruit Count
104
Registration Number
NCT04755712
Locations
🇫🇷

MAUPAIN, Quincy-sous-Sénart, France

Nebulized Heparin for the Treatment of COVID-19

Phase 4
Completed
Conditions
Covid19
Pneumonia, Viral
Interventions
First Posted Date
2021-01-25
Last Posted Date
2021-09-05
Lead Sponsor
Frederick Health
Target Recruit Count
50
Registration Number
NCT04723563
Locations
🇺🇸

Frederick Health Hospital, Frederick, Maryland, United States

ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients

Phase 3
Recruiting
Conditions
Traumatic Injury
Traumatic Brain Injury
Blunt Injury
Wounds and Injuries
Major Trauma
Penetrating Injury
Trauma
Multiple Trauma
Interventions
Drug: Epoetin Alfa 40000 UNT/ML
First Posted Date
2020-10-19
Last Posted Date
2023-10-03
Lead Sponsor
Australian and New Zealand Intensive Care Research Centre
Target Recruit Count
2500
Registration Number
NCT04588311
Locations
🇸🇦

King Abdulaziz Medical City, Riyadh, Saudi Arabia

🇮🇪

Cork University Hospital, Cork, Ireland

🇨🇭

St. Gallen Cantonal Hospital, Saint Gallen, Switzerland

and more 31 locations

Intraoperative Carbetocin to Decrease Blood Loss During Hysteroscopic Myomectomy

Phase 4
Completed
Conditions
Myoma;Uterus
Interventions
First Posted Date
2020-07-23
Last Posted Date
2022-04-06
Lead Sponsor
Mansoura University Hospital
Target Recruit Count
40
Registration Number
NCT04482959
Locations
🇪🇬

Faculty of Medicine, Mansoura, Dakahlia, Egypt

Methylene Blue in Early Septic Shock

Phase 2
Completed
Conditions
Septic Shock
Interventions
First Posted Date
2020-06-25
Last Posted Date
2022-11-04
Lead Sponsor
Hospital Civil de Guadalajara
Target Recruit Count
91
Registration Number
NCT04446871
Locations
🇲🇽

Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico

Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

Phase 2
Recruiting
Conditions
Covid19
Interventions
Drug: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)
First Posted Date
2020-06-24
Last Posted Date
2021-05-28
Lead Sponsor
Jon Simmons
Target Recruit Count
44
Registration Number
NCT04445285
Locations
🇺🇸

University of South Alabama, Mobile, Alabama, United States

A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)

Phase 2
Terminated
Conditions
COVID-19
Interventions
First Posted Date
2020-04-28
Last Posted Date
2023-03-29
Lead Sponsor
Renibus Therapeutics, Inc.
Target Recruit Count
42
Registration Number
NCT04364763
Locations
🇺🇸

New Smyrna Beach, FL, New Smyrna Beach, Florida, United States

🇺🇸

Berkley, MI, Berkley, Michigan, United States

🇺🇸

El Paso, TX, El Paso, Texas, United States

and more 2 locations

Effectiveness of Ketamine for Depression and Suicidal Ideation in the Emergency Department

Phase 4
Completed
Conditions
Depression Severe
Depression Acute
Depression and Suicide
Depression
Suicidal Ideation
Interventions
First Posted Date
2020-02-12
Last Posted Date
2020-09-01
Lead Sponsor
MercyOne Des Moines Medical Center
Target Recruit Count
29
Registration Number
NCT04266288
Locations
🇺🇸

MercyOne Des Moines Medical Center, Des Moines, Iowa, United States

A Study for Ureter Visualization, Using ASP5354 in Subjects Undergoing Laparoscopic/Minimally Invasive Colorectal Surgery

Phase 2
Completed
Conditions
Laparoscopic/Minimally Invasive Colorectal Surgery
Interventions
First Posted Date
2020-01-23
Last Posted Date
2024-10-24
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
13
Registration Number
NCT04238481
Locations
🇺🇸

Center for Colon and Rectal Surgery; AdventHealth Medical Group, Orlando, Florida, United States

🇺🇸

Ochsner Medical Center, New Orleans, Louisiana, United States

© Copyright 2025. All Rights Reserved by MedPath